Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Amuvatinib hydrochloride

😃Good
Catalog No. T14282Cas No. 1055986-67-8
Alias MP470 hydrochloride, HPK 56 hydrochloride

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally administered multi-targeted tyrosine kinase inhibitor effective against mutant forms of c-Kit, PDGFRα, Flt3, c-Met, and c-Ret, and it suppresses DNA repair by inhibiting the RAD51 protein, contributing to its antineoplastic activity[1][2][3][4].

Amuvatinib hydrochloride

Amuvatinib hydrochloride

😃Good
Catalog No. T14282Alias MP470 hydrochloride, HPK 56 hydrochlorideCas No. 1055986-67-8
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally administered multi-targeted tyrosine kinase inhibitor effective against mutant forms of c-Kit, PDGFRα, Flt3, c-Met, and c-Ret, and it suppresses DNA repair by inhibiting the RAD51 protein, contributing to its antineoplastic activity[1][2][3][4].
Pack SizePriceAvailabilityQuantity
25 mg$1,520Backorder
Bulk & Custom
Add to Cart
Questions
View More
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Amuvatinib hydrochloride (MP470 hydrochloride) is an orally administered multi-targeted tyrosine kinase inhibitor effective against mutant forms of c-Kit, PDGFRα, Flt3, c-Met, and c-Ret, and it suppresses DNA repair by inhibiting the RAD51 protein, contributing to its antineoplastic activity[1][2][3][4].
Targets&IC50
PDGFRα (D842V):81 nM, c-Kit (D816H):10 nM, PDGFRα (V561D):40 nM, c-Kit (V560G):34 nM, c-Kit (D816V):950 nM, c-Kit (V654A):127 nM
In vitro
Amuvatinib (MP470), a novel receptor tyrosine kinase (RTK) inhibitor has shown growth inhibitory activity against a variety of cancer cell lines. Amuvatinib (MP470) inhibits c-Kit (D816V), c-Kit (D816H), c-Kit (V560G), c-Kit (V654A), PDGFRα (D842V), and PDGFRα (V561D) with IC50s of 950 nM, 10 nM, 34 nM, 127 nM, 81 nM, and 40 nM, respectively[4]. Amuvatinib (0.1-10 μM, 4 days incubation) is effective on LNCaP and PC-3 cells with IC50s of ~4 μM and 8 μM, respectively. When Erlotinib (10 μM) is combined with varying doses of Amuvatinib, the IC50 of Amuvatinib decreases to 2 μM on LNCaP cells[5]. Akt activity (as measured by phosphorylation on Ser473) is significantly reduced by 10 μM Amuvatinib (treated for 30 hours) alone. However it is not reduced by Erlotinib or Imatinib Mesylate (IM). Amuvatinib plus Erlotinib completely abolished Akt phosphorylation in LNCaP cells with an unchanged total protein level of Akt[5].
In vivo
Four LNCaP xenograft groups, each consisting of 12 mice, are administered intraperitoneally with either DMSO (control), 80 mg/kg Erlotinib, 50 mg/kg Amuvatinib (MP470), or a combination of 80 mg/kg Erlotinib and 50 mg/kg Amuvatinib daily for 2 weeks, followed by an 11-day observation period. TGI in the group receiving 10 mg/kg Amuvatinib plus 80 mg/kg Erlotinib is not significantly different from the control, but mice receiving 20 mg/kg Amuvatinib plus 80 mg/kg Erlotinib show significant TGI compared to the control (p=0.01) [5]. Individual therapy with either Amuvatinib or Erlotinib induces modest TGI, whereas their combination results in a marked TGI (45-65%). Due to high doses, only five mice or one mouse in the combination arm survive until the end of treatment or the study, respectively. Consequently, the Amuvatinib dose is reduced to 10 mg/kg or 20 mg/kg for the combination treatment.
AliasMP470 hydrochloride, HPK 56 hydrochloride
Chemical Properties
Molecular Weight483.97
FormulaC23H22ClN5O3S
Cas No.1055986-67-8
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Amuvatinib hydrochloride | purchase Amuvatinib hydrochloride | Amuvatinib hydrochloride cost | order Amuvatinib hydrochloride | Amuvatinib hydrochloride chemical structure | Amuvatinib hydrochloride in vivo | Amuvatinib hydrochloride in vitro | Amuvatinib hydrochloride formula | Amuvatinib hydrochloride molecular weight